Intellia Therapeutics, Inc. (NTLA) Trading Down 5.5%
Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s share price was down 5.5% during mid-day trading on Friday . The stock traded as low as $21.30 and last traded at $21.31. Approximately 813,160 shares were traded during mid-day trading, an increase of 145% from the average daily volume of 331,782 shares. The stock had previously closed at $22.56.
Several equities analysts have issued reports on NTLA shares. Credit Suisse Group boosted their price target on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. ValuEngine raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Jefferies Group LLC set a $42.00 target price on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Leerink Swann upped their target price on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 31st. They noted that the move was a valuation call. Finally, Wedbush reaffirmed an “ourperform” rating and set a $25.00 target price (down from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $30.17.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. Intellia Therapeutics’s revenue for the quarter was up 49.0% on a year-over-year basis. equities analysts forecast that Intellia Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $101,000. Nisa Investment Advisors LLC purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at $134,000. Bank of Montreal Can raised its position in Intellia Therapeutics by 1,031.7% in the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after buying an additional 7,222 shares during the last quarter. Nationwide Fund Advisors raised its position in Intellia Therapeutics by 117.7% in the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after buying an additional 4,351 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at $160,000. 48.89% of the stock is currently owned by institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.